Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy

Journal of Surgical Oncology

Volumn 113, Issue 4, 2016, Pages 443-448

  Akinwande, Olaguoke ^a   Philips, Prejesh ^b   Scoggins, Charles R ^b   Kelly, Lawrence ^c   Tatum, Cliff ^c   Hahl, Mike ^d   McMasters, Kelly M ^b   Martin, Robert C G ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

^c Norton Healthcare   (United States)

^d Norton Cancer Institute   (United States)

Author keywords

chemoembolization; colorectal; DEBIRI; EASL; metastasis; mRECIST; RECIST

Indexed keywords

DOXORUBICIN; IRINOTECAN; CAMPTOTHECIN; TUMOR MARKER; YTTRIUM;

ABLATION THERAPY; ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; IMAGING; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; OVERALL SURVIVAL; PATIENT HISTORY OF SURGERY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOEMBOLIZATION; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SURVIVAL ANALYSIS; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; METASTASIS; MIDDLE AGED; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CAMPTOTHECIN; CHEMOEMBOLIZATION, THERAPEUTIC; COLORECTAL NEOPLASMS; DOXORUBICIN; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; YTTRIUM RADIOISOTOPES;

EID: 84963676501     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.24141     Document Type: Article

References (17)

1. Sharma MR, Maitland ML, Ratain MJ,: RECIST: No longer the sharpest tool in the oncology clinical trials toolbox-point. Cancer Res 2012; 72: 5145-5149; discussion 5150.
2. Sharma MR, Maitland ML, Ratain MJ,: Why RECIST works and why it should stay-reply to counterpoint. Cancer Res 2012; 72: 5158.
3. Jung ES, Kim JH, Yoon EL, et al.,: Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol 2013; 58: 1181-1187.
4. Memon K, Kulik L, Lewandowski RJ, et al.,: Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011; 141: 526-535; 535 e521-522.
5. Prajapati HJ, Spivey JR, Hanish SI, et al.,: MRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol 2013; 24: 965-973.
6. Shim JH, Lee HC, Kim SO, et al.,: Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 2012; 262: 708-718.
7. Chapiro J, Duran R, Lin M, et al.,: Early survival prediction after intra-arterial therapies: A 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. Eur Radiol 2015.
8. Egger ME, Cannon RM, Metzger TL, et al.,: Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor. J Am Colg Surg 2013; 216: 845-856; discussion 856-847.
9. Akinwande O, Miller A, Hayes D, et al.,: Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer. Anticancer Res 2014; 34: 7239-7245.
10. Martin RC, Joshi J, Robbins K, et al.,: Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: Results of multi-institutional study. Ann Surg Oncol 2011; 18: 192-198.
11. Woodall CE, Scoggins CR, Ellis SF, et al.,: Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis ? J Amn Colg Surg 2009; 208: 375-382.
12. Jones RP, Stattner S, Dunne DF, et al.,: Radiological assessment of response to neoadjuvant transcatheter hepatic therapy with irinotecan-eluting beads (DEBIRI((R))) for colorectal liver metastases does not predict tumour destruction or long-term outcome. Eur J Surg Oncol 2013; 39: 1122-1128.
13. Forner A, Ayuso C, Varela M, et al.,: Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable ? Cancer 2009; 115: 616-623.
14. Gillmore R, Stuart S, Kirkwood A, et al.,: EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011; 55: 1309-1316.
15. Kim BK, Kim KA, Park JY, et al.,: Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. Eur J Cancer 2013; 49: 826-834.
16. Jang HJ, Kim BC, Kim HS, et al.,: Comparison of RECIST 1.0 and RECIST 1.1 on computed tomography in patients with metastatic colorectal cancer. Oncology 2014; 86: 117-121.
17. Kim JH, Min SJ, Jang HJ, et al.,: Comparison of RECIST 1.0 and RECIST 1.1 in patients with metastatic cancer: A pooled analysis. J Cancer 2015; 6: 387-393.